

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:	:	
	:	Confirmation No. 3314
Gerald Cagle et al.	:	
	:	Group Art Unit: 1618
Application No. 10/715,055	:	
	:	Examiner: Fay, Zohreh A.
Filed: November 17, 2003	:	
	:	Atty Dkt No.: 007109.00001
For: METHOD OF TREATING	:	
OPHTHALMIC INFECTIONS WITH	:	
MOXIFLOXACIN COMPOSITIONS	:	

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Submitted herewith is a copy of the October 19, 2009 opinion of the district court in the previously-identified Delaware litigation involving parent U.S. Patent 6,716,830. The district court ruled, *inter alia*, that the defendant “Teva has failed to prove, by clear and convincing evidence, that the ’830 [patent] is invalid as anticipated, obvious, or for violation of the best mode, written description or enablement requirements of 35 U.S.C. § 112, ¶ 1.” (p. 49).

Respectfully submitted,

Date: October 26, 2009

By: /Paul M. Rivard/  
Paul M. Rivard  
Registration No. 43,446  
BANNER & WITCOFF, LTD.  
1100 13<sup>th</sup> Street N.W., Suite 1200  
Washington, DC 20005-4051  
(202) 824-3000 (telephone)  
(202) 824-3001 (facsimile)